Top story · September 14, 2026
Deborah Kadagian founded the Solas Foundation to expand ibogaine access.
Deborah Kadagian founded the Solas Foundation to provide ibogaine treatment grants, driven by personal and professional insights.
Read the storySeptember 14, 2026
New Texas-based entity to spearhead ibogaine research and development in the US.
September 14, 2026
New subsidiary aims to centralize ibogaine supply and regulatory efforts in the U.S.
September 14, 2026
Texas Ibogaine Research Corporation to spearhead U.S. ibogaine development efforts.
September 13, 2026
Ibogaine treatment journey highlights familial love and resilience.
September 13, 2026
FDA approval of psychedelics like ibogaine could influence Japanese pharmacy practices.
September 13, 2026
Driver allegedly held over 200 grams of psychedelic opioids.
September 11, 2026
Ibogaine offers a novel approach to opioid detox, but carries significant risks.
September 10, 2026
Filament Health begins stability testing for IBEX011, a botanical ibogaine drug.
September 10, 2026
Filament Health begins stability program for IBEX011 amid rising ibogaine demand.
September 10, 2026
Universal Ibogaine's stock price holds steady as the company navigates restructuring challenges.
September 10, 2026
The FDA highlights its evolving approach to psychedelic therapies amid a mental health crisis.
September 10, 2026
IBEX011 stability program aims to meet growing demand for standardized ibogaine.
September 8, 2026
Jonathan Dickinson's new book explores ibogaine's therapeutic potential amid rising U.S. policy focus.
September 4, 2026
States advised to anticipate FDA approval of psychedelics for medical use.
September 3, 2026
Veterans push for ibogaine to treat PTSD and addiction.
September 2, 2026
The filing could signal strategic developments for the company.
September 1, 2026
The study aims to explore ibogaine's potential for treating PTSD and addiction.
September 1, 2026
Pharmaceutical companies increase ad budgets for psychedelic terms as ARPA-H funds ibogaine studies.
August 29, 2026
David Dardashti's clinic highlights ten years of treating kratom addiction with ibogaine.
August 27, 2026
American tourist's death highlights risks of unregulated psychedelic retreats in Costa Rica.
August 27, 2026
Israel urged to engage in psychedelic research and development.
August 27, 2026
Gabon establishes national framework to govern iboga, aiming to benefit local communities.
August 26, 2026
Recent deaths highlight risks in unregulated psychedelic retreats.
August 26, 2026
Ibogaine treatments in Mexico raise safety concerns for U.S. patients.
August 26, 2026
Ibogaine shows promise for PTSD, but remains illegal in the U.S.
August 26, 2026
The move promotes open science and could influence future psychedelic research.
August 25, 2026
New framework investigates ibogaine's potential in treating postpartum depression.
August 24, 2026
O'Neill discusses his skepticism about the reported shooting involving Charlie Kirk.
August 21, 2026
The move could expedite psychedelic research for veteran treatment.
August 21, 2026
Investment in neuroplastogen company highlights growing interest in non-hallucinogenic psychedelics.
August 21, 2026
David Dardashti shares clinical footage as psychedelic therapy gains federal interest.
August 21, 2026
Trump administration accelerates psychedelic research for veterans' mental health.
August 20, 2026
Dr. Heidi Overton, nominated by Trump, expedited psychedelic research policy.
August 20, 2026
Audacy's latest episode delves into intuitive communication.
August 20, 2026
Nominee previously advocated for tighter controls on abortion medications.
August 19, 2026
University of Miami's 1994 ibogaine application resurfaces, boosting market interest.
August 19, 2026
Barrow Neurological Institute to test ibogaine's safety and efficacy in a state-funded trial.
August 19, 2026
Heidi Overton's nomination could advance psychedelic therapies but raises vaccine concerns.
August 19, 2026
Trump's administration advances psychedelic therapies for PTSD and TBI in veterans.
August 19, 2026
U.S. federal actions could accelerate ibogaine's medical potential
August 19, 2026
U.S. backing could accelerate ibogaine research for mental health.
August 19, 2026
Rising tensions in the Strait of Hormuz raise global concerns over oil transit.
August 19, 2026
Former President Trump advocates for psychedelic treatment to aid veterans.
August 19, 2026
Market optimism grows as Psyence Biomedical advances ibogaine studies.
August 19, 2026
Former President Trump supports ibogaine research, sparking industry response.
August 19, 2026
Company aligns with U.S. efforts to advance ibogaine research.
August 19, 2026
The executive order aims to expedite research on ibogaine and other psychedelics.
August 19, 2026
Ibogaine, a psychedelic drug, gains federal attention for treating addiction.
August 19, 2026
Trump announces transfer of ibogaine investigational drug application to accelerate research.
Newsletter
Occasional dispatches on research, policy, and treatment. No spam.